Ecopipam as a pharmacologic treatment of stuttering
Gerald A Maguire1, Lisa LaSalle, Debra Hoffmeyer
1Professor and Chair of Psychiatry and Neuroscience, University of California, Riverside, School of Medicine, CA 92521 USA.
Background:
Stuttering, also known as childhood-onset fluency disorder, is a chronic neurodevelopmental disorder that affects 1% of the population and can greatly impact an individual's social, occupational, and academic functioning. Prior research has shown dopamine D2 antagonists are effective in reducing the severity of stuttering symptoms, but these compounds can be associated with metabolic and movement disorder adverse effects. Ecopipam is an investigational medication that acts as a selective dopamine D1 receptor antagonist. This mechanism should reduce the likelihood of metabolic and movement disorder adverse effects of D2 antagonists.
Method:
This open-label pilot study investigated ecopipam in the treatment of adults who stutter.
Results:
The results showed that a majority of participants demonstrated improvement in their stuttering. The medication was well tolerated.
Conclusions:
These positive, preliminary findings suggest that a doubleblind, randomized controlled clinical trial to examine the efficacy of ecopipam in the treatment of stuttering is warranted.
Related Concept Videos
01:28Cholinergic Antagonists: Pharmacological Actions
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
01:15Drug Abuse and Addiction: Pharmacological Phenomena
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:25Factors Influencing Drug Absorption: Disease States and Pharmacology
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions